Back to Search
Start Over
The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.
- Source :
-
International journal of STD & AIDS [Int J STD AIDS] 2014 Apr; Vol. 25 (5), pp. 332-40. Date of Electronic Publication: 2013 Oct 08. - Publication Year :
- 2014
-
Abstract
- By comparing younger to older participants enrolled in a HIV vaccine efficacy trial, we aimed to gain insights into the inclusion of adolescents in future trials. This was a sub-analysis of a multisite HIV vaccine randomized clinical trial in South Africa, conducted January-September 2007. Motivations for trial enrolment, social harms, adverse events and loss to follow-up were compared between younger (18-20 years old) and older participants (21-35 years old). Both younger (n = 238) and older participants (n = 563) were equally likely to report enrolling for altruistic reasons. Younger females were less likely than older participants to join for trial reimbursement (p = 0.005), while younger males were more likely to enrol because the vaccine may provide protection from HIV-acquisition (p < 0.001). There were no significant differences in the number of social harms reported. Compared to males over 20 years old, 18-20-year-old females were less likely to experience adverse events (OR = 0.1, CI 0.01-0.80) and no more likely to be lost to follow-up (OR = 0.7, CI 0.39-1.25), while 18-20-year-old males were no more likely to experience adverse events (OR = 1.3, CI 0.58-2.83) or loss to follow-up (OR = 0.8, CI 0.51-1.41). Our data support the inclusion of younger participants who are at risk for HIV in future HIV vaccine efficacy trials.
Details
- Language :
- English
- ISSN :
- 1758-1052
- Volume :
- 25
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- International journal of STD & AIDS
- Publication Type :
- Academic Journal
- Accession number :
- 24104693
- Full Text :
- https://doi.org/10.1177/0956462413506892